Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

Elevated plasma fibrinogen : Cause or consequence of cardiovascular disease?

Publication files not online:

Author: Bom, J.G. van der · Maat, M.P.M. de · Bots, M.L. · Haverkate, F. · Jong, P.T.V.M. de · Hofman, A. · Kluft, C. · Grobbee, D.E.
Type:article
Date:1998
Institution: Gaubius Instituut TNO
Source:Arteriosclerosis, Thrombosis, and Vascular Biology, 4, 18, 621-625
Identifier: 234449
doi: DOI:10.1161/01.ATV.18.4.621
Keywords: Health · β- fibrinogen gene · -455G/A polymorphism · Cardiovascular disease risk · HaeIII polymorphism · Thrombotic tendency · Aged · Blood Pressure · Cardiovascular Diseases · Case-Control Studies · Cholesterol · Cholesterol, HDL · Cross-Sectional Studies · Female · Fibrinogen · Genotype · Humans · Male · Middle Aged · Myocardial Infarction · Polymerase Chain Reaction · Polymorphism, Genetic · Risk Factors · Smoking

Abstract

An association between increased plasma fibrinogen and an increased risk for myocardial infarction (MI) is well established, but the nature of this association is subject to debate. Our aim was to shed light on the potentially causal nature of this association. We examined whether increased plasma fibrinogen, due to a condition that is independent of cardiovascular events, also increases the risk for MI. A case-control study was performed in 139 subjects with a history of MI and 287 control subjects selected from the Rotterdam Study, a population-based cohort of 7983 subjects aged 55 years and older. The genotype of the -455G/A polymorphism in the fibrinogen β-gene was determined by polymerase chain reaction. Functional-plasma fibrinogen levels were determined according to yon Clauss. The plasma level of fibrinogen was significantly higher in subjects with one or two A alleles compared with subjects with the GG genotype: 3.8 (95% confidence interval [CI], 3.6 to 3.9) g/L and 3.6 (3.5 to 3.7) g/L, respectively. With increasing plasma fibrinogen level, the risk for MI increased gradually; a rise in fibrinogen of 1 g/L was associated with a 45% increased risk (odds ratio adjusted for age, sex, and smoking, 1.45; 95% CI, 1.12 to 1.88). There was no association between the genotype of the -455G/A polymorphism and the risk for MI. The -455G/A polymorphism is therefore associated with increased plasma fibrinogen levels but not with an increased risk for MI. These findings indicate that an increased plasma fibrinogen level due to this genetic factor does not increase the risk for MI.